BioSpace News Archive

Ascendis Pharma A/S (Nasdaq: ASND) today announced that its presentations at ENDO 2022 will include oral presentations of Phase 2 and Phase 3 data for its investigational product candidate TransCon PTH in adult hypoparathyroidism (HP).

Ashvattha Therapeutics announced a poster presentation of preclinical data demonstrating its hydroxyl dendrimer-based therapeutics reduce toxicity in targeted delivery to plexiform neurofibroma, a slow growing tumor associated with neurofibromatosis type 1, at the 2022 Neurofibromatosis Conference hosted by the Children’s Tumor Foundation and taking place at Loews Philadelphia Hotel in Philadelphia, PA, June 18 – 21, 2022.

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, announced today that it has entered into a committed equity purchase agreement (the “Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), for the issuance and sale, from time to time, of up to $40 million of its American Depositary Shares.

AbbVie (NYSE: ABBV) today announced it will present data from its migraine portfolio at the 2022 American Headache Society (AHS) Annual Scientific Meeting to be held in Denver, June 9-12.

Freenome, a privately held biotech company, presented findings at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting that demonstrate the clinical utility of detecting not just colorectal cancer (CRC), but also precancerous adenomas in a Medicare-aged cohort for tests that screen for CRC and multi-cancer early detection (MCED) tests that include CRC.

When health systems and hospitals use regulated reprocessed “single-use” devices, they reduce procedure costs without compromising patient safety, build supply chain resilience and help governments and hospitals get to net zero carbon emissions faster.

NorthStar Medical Radioisotopes, LLC (‘NorthStar’), and Curie Therapeutics Inc., a therapeutics company dedicated to transforming cancer care with precision radiopharmaceuticals, today announced the signing of a long-term priority access supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

ENX-101 exhibited a favorable safety and pharmacokinetic profile in healthy volunteers.

Massive Bio, Inc. and AdhereTech announced their partnership to provide advanced, data-driven digital health technology solutions.

Pharvaris today announced the presentation of its development program at the Kinin 2022 Conference, to be held June 5-8, 2022, in Annecy, France.